Compare Costco Wholesale Corporation (COST) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Sanofi SA — how do they compare? Costco Wholesale Corporation trades at $948.52 (market cap $418.79B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Costco Wholesale Corporation is far larger — about 4× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| COST | SNY | |
|---|---|---|
Market Cap | $418.79B | $104.30B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $52.34 |
52-Week Low | $849.63 | $41.33 |
Enterprise Value | $406.93B | $124.19B |
Dividend Yield | 0.62% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco Wholesale Corporation (COST) trades at $948.1, down 0.49% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $275.24B in 2025 and net income of $8.10B, though it missed Q1 2026 EPS estimates. Recent news highlights March sales up 11.3% year-over-year and institutional buying activity, while the stock remains near its 52-week high of $1,067.08.
Outlook is supported by robust membership fee growth and expansion, but high valuation ratios like a P/E of 47.5 pose risks. Analyst consensus is bullish with a $1,120 price target, though competitive pressures and economic sensitivity could challenge margins. The stock offers long-term growth potential if valuation aligns with earnings momentum.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
